Rindopepimut with bevacizumab for patients with relapsed EGFRvIII-expressing glioblastoma (REACT): Results of a double-blind randomized phase II trial

for the ReACT trial investigators

Research output: Contribution to journalArticle

6 Scopus citations

Fingerprint Dive into the research topics of 'Rindopepimut with bevacizumab for patients with relapsed EGFRvIII-expressing glioblastoma (REACT): Results of a double-blind randomized phase II trial'. Together they form a unique fingerprint.

Medicine & Life Sciences